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List of abbreviations 
 
Bak: Bcl-2 homologous Antagonist/Killer 
Bax: Bcl-2 associated X protein 
Bcl-2: B-cell lymphoma 2 
BH: Bcl-2 homology 
BSA: bovin serum albumin 
6-CF: 6-carboxyfluorescein 
Cx: connexin 
DMSO: dimethyl sulfoxide 
DTMR: dextran, tetramethylrhodamine 
ERK: extracellular signal-regulated kinase 
FBS: fetal bovine serum 
GA: 18-glycyrrhetinic acid 
GJ: gap junction 
GJIC: gap junctional intercellular communication 
JC-1: 5, 5’, 6, 6’-tetrachloro-1, 1’, 3, 3’-tetraethylbenzimidazolocarbocyanine iodide 
JNK: c-jun N-terminal kinase 
MAPK: mitogen-activated protein kinase 
MM: malignant mesothelioma 
MTT: 3-(4, 5-dimetylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
PBS: phosphate buffered saline 
PDGF(R): platelet-derived growth factor (receptor) 
PKC: protein kinase C 
RNA: ribonucleic acid 
ROS: reactive oxygen species 
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RTK: receptor tyrosine kinase 
SAPK: stress-activated protein kinase 
siRNA: short-interfering RNA 
SU: sunitinib 
TBS(-T): Tris buffered saline (and tween 20) 
VEGF(R): vascular endothelial growth factor (receptor)
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Backgrounds 
 
Connexin (Cx) is a four-transmembrane protein and forms an intercellular channel 
called gap junction (GJ). Cellular homeostasis, growth, and differentiation are 
mediated via GJ intercellular communication (GJIC) (1). GJ allows a direct transfer of 
several second messengers and small molecules between apposed cells, including 
Ca2+ , cyclic adenosine 3’, 5’-monophosphate (cAMP), cyclic guanosine 3’, 5’-
monophosphate (cGMP), inositol 1, 4, 5-triphosphate (IP3), and glutathione (2). 
Twenty-one Cx subtypes are expressed in human (3), with some members being 
only expressed in specific tissues, while others including connexin 43 (Cx43) and 
Cx32, expressed ubiquitously (4). Each subtype makes GJ and maintains the cellular 
network in the expressed tissue. For example, it has been reported that molecular 
transfer between astrocytes via GJ made up of Cx43 and Cx30, which are major Cx 
subtypes in these cells, affects the synaptic activity of nearby neurons in the brain 
(5). Recently, it has been recognized that Cx is not just a component of GJ, but also 
it interacts with various proteins including Src (6), extracellular signal-regulated 
kinase (ERK) (7), S-phase kinase associated protein (Skp) 2 (8), B-cell lymphoma 2 
(Bcl-2) associated X protein (Bax) (9), and -catenin (10), and affects them in their 
expressions or activities (11). From these facts, it is surmised that aberrant function 
of Cx and GJ would be caused by or lead to many types of diseases. 
 
Frequently, it has been observed that Cx expression is decreased accompanied by 
decreased GJ function in many cancer cells (4). Several Cx gene transfection 
experiments have suggested that Cx-mediated GJIC works as a tumor suppressor in 
cells where a specific Cx subtype was originally expressed (12). It has also been 
shown that Cx43 reduces cell growth in the absence of GJIC (13), suggesting that 
direct molecular interaction of Cx has a crucial role in its tumor suppressive effect. 
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However, restoring Cx expression is not always sufficient to inhibit tumor 
proliferation. In our previous study, transfection of Cx43 gene in malignant 
mesothelioma (MM) cells did not change the ability of anchorage-independent growth 
and migration. Thus, we combined increased Cx43 expression with a treatment of 
cisplatin and showed that Cx43 enhanced its cytotoxicity in MM cells (14). Another 
group reported that transfection of Cx43 gene increased tumor suppressive effect of 
docetaxel in a prostate cancer xenograft model (15). Moreover, we confirmed that 
Cx32 enhanced cytotoxicity of vinblastine and vinorelbine in renal and lung cancer 
cell lines, respectively (16, 17). These studies indicate that combination of Cx and 
anti-cancer agents would be a promising strategy for cancer chemotherapy. Although 
our previous works have already found a proto-oncogenic tyrosine kinase Src, as a 
key molecule for both Cx43 and Cx32 to enhance drug sensitivity in cancer cells, 
further investigation into other proteins with which Cx interacts can broaden the 
potential of Cx for a target of cancer therapy. Especially, targeting direct modulators 
of cell survival/death will be beneficial. 
 
Therefore, we turned our attention to the report that showed a direct interaction 
between Cx43 and Bax, as this interaction promoted induction of apoptosis in 
pancreatic cancer cells (9). Bax is a major proapoptotic protein of the Bcl-2 family, 
which causes mitochondrial dysfunction followed by caspase activation in process of 
apoptosis. Bax is a clinically important protein, since it has been reported that the 
higher Bax expression level is correlated with the favorable clinical outcomes in 
patients with gastric and breast tumors (18, 19). With a view to increasing Bax 
function, we investigated a beneficial combination of Cx43 with an anti-cancer agent 
in MM cells, whose original mesothelial cells express Cx43 as the major Cx subtype 
(14). 
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MM is an insidious tumor, whose main risk factor is inhalation of asbestos. MM 
displays a long latency period of over 40 years following the first exposure to 
asbestos (20). Asbestos is a fire-resistant material that was widely used in various 
industries between the 1940s and the 1970s, with MM incidence increasing 
throughout the world (21). For example, the incidence of MM is currently 2000-3000 
per year in the United States, and approximately 70,000 new MM cases are expected 
over the next 20 years (22). In Europe, the peak year of MM incidence is anticipated 
to fall between 2015 and 2020, with estimated 250,000 new cases over the next 40 
years (22). Surgery is desirable for MM patients in clinical stage I; however, the 
majority of patients are diagnosed at an advanced stage, and the only treatment 
option for them is systemic therapy (23). Unfortunately, MM is usually a chemo- and 
radio-resistant tumor, which contributes to its poor prognosis (23). Although a 
platinum-based chemotherapy has been used for the MM patients now, its impact on 
the survival of these patients is modest (24). What is worse, there is no second-line 
treatment. Such unmet clinical need and progression in the identification of key 
growth factors, glycoproteins, and genetic mutations in MM tumorigenesis have 
generated an interest in the development of novel agents to target these oncogenic 
abnormalities (20). It has been reported that both vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor (PDGF) play an important role in the 
growth of MM cells via the autocrine loops (25, 26). Moreover, the higher VEGF 
expression in MM tissues was correlated with a poor prognosis for the patients (27). 
Based on these observations, it is rational to target these signaling pathways. Thus, 
we turned our attention to sunitinib (SU). SU is a multi-targeted tyrosine kinase 
inhibitor, which suppresses the activation of VEGF receptors (VEGFRs 1-3), PDGF 
receptors (PDGFRs α and β), and other growth factor receptors (28). 
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This study describes the effect of increased Cx43 expression on SU-induced 
cytotoxicity in MM cells. This thesis is composed of two chapters; in the first chapter, 
the efficacy of a combination of Cx43 and SU in MM cells is described, while the 
second chapter describes our investigation into the detailed mechanism by which 
Cx43 enhanced SU-induced cytotoxicity.    
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Chapter 1 Cx43 enhances SU-induced cytotoxicity in corporation with Bax 
 
Introduction 
 
Cell death is deeply related to cancer therapy. Originally, cell death had been 
recognized as “necrosis”, which is caused by noxious stimuli and often accompanied 
by atrophy of tissues and organs. In 1972, Kerr et al. defined the cell death 
characterized by nuclear and cytoplasm condensation as “apoptosis” in distinction 
from necrosis (29). Cells exhibiting such distinct structure were observed in damaged 
and healthy tissues of adult and neonatal rats by electron microscopy, which 
suggests that apoptosis is involved in tissue development and maintenance. The 
mechanism of how this process is regulated had been unknown for a long time since 
that discovery. In 1985, Tsujimoto et al. isolated Bcl-2 gene at the chromosomal 
breakpoint of t(14;18)-bearing follicular B cell lymphomas (30), and it was shown that 
overexpression of Bcl-2 enabled certain hematopoietic cell lines to survive following 
apoptosis induced by the growth factor withdrawal (31, 32). It was also found that it is 
localized at the mitochondrial membrane, which was a unique characteristic of a 
protein with a proto-oncogenic role at that time. Presently, Bcl-2 is widely recognized 
as a cell death repressor protein. In 1993, Bax was identified as a 21 kilodalton 
protein, which was coimmunoprecipitated with Bcl-2 (33). Bax shows homology with 
Bcl-2 with 20.8% identity and 43.2% similarity in amino acid sequence. 
Overexpression of Bax in murine lymphoid progenitor cells enhanced apoptosis 
caused by the growth factor withdrawal, and it was shown that expression ratio of 
Bax to Bcl-2 affected the sensitivity of that cell line to apoptotic stimulation. Whereas 
many types of conventional cytotoxic agents cause apoptosis in cancer cells (34), the 
Bcl-2/Bax ratio is considered an important indicator of the sensitivity of cancer cells to 
anti-cancer agents. Now, proteins which contain the conserved Bcl-2 homology (BH) 
domain are classified into the Bcl-2 family member and further subdivided into 3 
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groups according to their structures and functions: anti-apoptotic Bcl-2-like proteins, 
proapoptotic multidomain proteins including Bax and Bcl-2 homologous 
Antagonist/Killer (Bak), and proapoptotic BH3-only proteins (35). These proteins are 
expected to regulate apoptosis arising from mitochondrial dysfunction by interacting 
with one another. 
 
Since increasing Bax function can be beneficial for the treatment of any types of anti-
cancer agents, this chapter describes our investigations of whether Cx43 enhances 
SU-induced cytotoxicity, and the potential contribution of Bax to the enhanced 
cytotoxicity. 
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1-1 Effect of Cx43 on anti-proliferative effect of SU 
 
In chapter 1-1, it was investigated whether Cx43 enhances the growth inhibitory 
effect of SU in MM cells. In addition, the activity of receptor tyrosine kinase (RTK) 
signaling was evaluated, because it is a target of SU. 
 
1-1-1 Materials and Methods 
 
Reagents  
All cultures and reagents were purchased from Sigma (St. Louis, MO, USA) unless 
otherwise indicated.  
・30% Acrylamide solution (Bio-Rad, Hercule, CA, USA) 
・Bovine serum albumin (BSA)  
・Bromophenol blue (ICN Biomedicals, Eschwege, Germany) 
・3-(4,5-Dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Dojindo 
Laboratories, Kumamoto): 5 mg/mL stock solution in distilled water was used. 
・Dimethyl sulfoxide (DMSO; Wako Pure Chemicals, Osaka) 
・Dulbecco’s PBS (-) (PBS; Nissui Pharmaceutical Co., Ltd., Tokyo) 
・Ethanol (99.5) (Wako Pure Chemicals) 
・Ethylenediaminetetraacetic acid (Dojindo Laboratories) 
・Fetal bovine serum (FBS; Biowest, Kansas City, MO, USA) 
・β-Glycerophosphate 
・2-Mercaptoethanol (Wako Pure Chemicals) 
・Penicillin-Streptomycin (Gibco, Palo Alto, CA, USA) 
・Phenylmethane sulfonyl fluoride 
・Polyoxyethylene (10) Octylphenyl Ether (TritonX-100; Wako Pure Chemicals) 
・Polyoxyethylene (20) Sorbitan Monolaurate (Tween 20; Wako Pure Chemicals) 
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・Propidium iodide (PI; Invitrogen, Carlsbad, CA, USA): 1 mg/mL stock solution in 
distilled water was used. 
・Protease inhibitor cocktail 
・RNaseA (MP Biomedicals, Santa Ana, CA, USA): 10 mg/mL stock solution in 10 
mM sodium acetate buffer (pH 5.2) was used. 
・RPMI-1640 medium 
・Skim milk (Megmilk Snow Brand, Co., Ltd., Tokyo) 
・Sodium acetate buffer solution 
・Sodium chloride (NaCl; Wako Pure Chemicals) 
・Sodium dodecyl sulfate (SDS; Wako Pure Chemicals) 
・Sodium orthovanadate 
・Sucrose (Wako Pure Chemicals) 
・Sunitinib malate (SU): 10 or 100 mM stock solution in DMSO was used. 
・5, 5’, 6, 6’-tetrachloro-1, 1’, 3, 3’-tetraethylbenzimidazolocarbocyanine iodide (JC-
1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA): 1.5 mM stock solution in 
DMSO was used. 
・0.25% Trypsin-EDTA Solution 
・UltraPure™ Tris (Tris; Invitrogen) 
 
Cell culture, construct creation, and transfection 
H28, a representative human MM cell line, was obtained from ATCC (Manassas, VA, 
USA) and grown in RPMI-1640 medium supplemented with 10% FBS, 100 units/mL 
penicillin/100 μg/mL streptomycin at 37°C in 5% CO2. Cx43-transfected H28 cells 
(H28-T) were produced as previously described (14). In brief, a human Cx43 cDNA 
containing the entire coding region was inserted into the expression vector pcDNA™ 
3.1 D/V5-His-TOPO® (Invitrogen), and it was transfected into H28 cells by using 
FuGENE® HD Transfection Reagent (Roche Applied Science, Pleasanton, CA, 
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USA), and the cells were then selected in a culture medium containing 0.7 mg/mL 
G418. Wild-type cells (H28-W) were used as a control. 
 
Cell viability assay 
A total of 5.0 × 103 cells were seeded in a 96-well plate. After 24 h incubation, the 
cells were treated with 0.38-10 μM SU or DMSO (control) followed by culturing for 24 
h. At the end of the period, 0.25 mg/mL MTT was added to each well and the plate 
was incubated for 1 h. The supernatant was removed and DMSO was added to each 
well. The absorbance at a wavelength of 540 nm and a reference wavelength of 650 
nm was measured with a Multiscan™ JX microplate reader (Thermo Labsystems, 
Cheshire, UK). Cell viability (%) was calculated as follows: [optical density (OD) of 
the treated cells] / (OD of the control cells) × 100. 
 
Cell cycle analysis 
A total of 1.5 × 105 H28-W cells and 3.0 × 105 H28-T cells were seeded in 60 mm 
dishes. After 6 h incubation, the cells were cultured in medium containing 0.1% FBS 
for 24 h followed by treatment with 10 μM SU or DMSO (control) for each indicated 
period. Then, the cells were collected and fixed in 80% ethanol. Before analysis, the 
cells were incubated in PBS containing 50 μg/mL PI and 200 μg/mL RNaseA for 30 
min at 37°C. The cell suspension was filtered through a nylon mesh filter, and the 
filtrate was analyzed using a BD FACSCanto™ II flow cytometer (BD Biosciences, 
San Jose, CA, USA). 
 
Measurement of mitochondrial membrane potential 
A total of 3.2 × 105 cells were seeded in a 6-well plate. After 24 h incubation, the cells 
were treated with 5 or 10 M SU or DMSO (control) followed by culturing for 8 h. 
Then, cells were trypsinized and incubated with 1 M JC-1 for 20 min at 37°C. After 
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that, cells were washed and resuspended in PBS. Fluorescence of JC-1 monomers 
was measured at 485 nm excitation and 535 nm emission, and that of JC-1 
aggregates was measured at 550 nm excitation and 600 nm emission by using 
SpectraMax™ i3 (Molecular Devices, Sunnyvale, CA, USA).  
 
Western blot analysis 
A total of 1.5 × 105 H28-W cells and 3.0 × 105 H28-T cells were seeded in 60 mm 
dishes. After 6 h incubation, the cells were cultured in 0.1% FBS medium for 24 h 
followed by treatment with 10 μM SU or DMSO (control) for each indicated period. 
Cells were collected by scraping and dissolved in ice-cold lysis buffer [50 mM Tris 
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 10 mM β-glycerophosphate, 1 mM sodium 
orthovanadate, 1 mM ethylenediaminetetraacetic acid, 1mM phenylmethane sulfonyl 
fluoride, and 1% protease inhibitor cocktail]. Protein concentrations were determined 
by using a DC protein assay kit (Bio-Rad). Total cell lysates (10 μg or 25 μg) were 
diluted in sample buffer [250 mM Tris (pH 6.8), 40% sucrose, 20% 2-
mercaptoethanol, 8% SDS, and 0.002% bromophenol blue] and separated using a 
7.5% or 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gel. The 
separated proteins were then transferred to a polyvinylidene difluoride membrane 
(ATTO, Tokyo). After that, the membranes were blocked with 5% skim milk in tris-
buffered saline and tween 20 (TBS-T) [13.7 mM NaCl, 25 mM Tris, and 0.05% 
Tween 20] or 5% BSA in TBS-T for 1 h at room temperature or overnight at 4°C. The 
membranes were then incubated with primary antibodies for 1 h at room temperature 
or overnight at 4°C followed by incubation with secondary horse radish peroxidase 
(HRP)-conjugated antibodies diluted in TBS-T containing 1% skim milk for 1 h at 
room temperature. The primary antibodies are shown in Table 1. The detection was 
accomplished using an Immobilon™ Western Chemiluminescent HRP Substrate 
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(Merck Millipore, Darmstadt, Germany) and an ImageQuant™ LAS 4000 (GE 
Healthcare). β-Actin was used as the internal standard. 
 
Statistical analysis 
Statistical analyses were performed by using the Student’s t-test, the Aspin-Welch’s 
t-test, or the Tukey-Kramer test. A value of P < 0.05 was considered statistically 
significant. 
 
Table 1 The primary antibodies used in western blot analysis
Target Source Cat. No. dilution TBS-T with Incubation Species
VEGFR2
Cell Signaling Technologies
(Danvers, MA, USA)
#2479 1000 5% BSA on, 4°C rabbit
PDGFR Santa Cruz Biotechnology sc-53872 1000 5% BSA on, 4°C mouse
p44/42 MAPK (Erk1/2)
(137F5): ERK
Cell Signaling Technologies #4695 5000 1% skim milk on, 4°C rabbit
Phopho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204): p-ERK
Cell Signaling Technologies #9101 2000 5% BSA on, 4°C rabbit
Akt (pan) (C67E7): Akt Cell Signaling Technologies #4691 5000 1% skim milk on, 4°C rabbit
Phopho-Akt (Ser473): p-Akt Cell Signaling Technologies #9271 2000 5% BSA on, 4°C rabbit
-Actin Sigma A5441 10000 1% skim milk 1 h, rt mouse
rt: room temperature; on: overnight 
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1-1-2 Results 
 
First, the effect of Cx43 on the sensitivity of MM cells to SU was examined. It was 
shown that H28-W cells were resistant to SU; approximately 80% of the cells 
survived even after a 24 h exposure to 10 M SU (Fig. 1-1-1). In contrast, the viability 
of Cx43-transfected H28-T cells was significantly lower than that of H28-W cells in 
the presence of SU in a 0.38-10 M range. Particularly, less than half of the control 
cells survived after 24 h of treatment with 10 μM SU. 
  
Next, we examined the effect of Cx43 expression on the cell cycle. The S-phase 
population in H28-T cells was significantly higher than in H28-W cells at every time 
point (Fig. 1-1-2A). SU had almost no impact on cell cycle distribution except for a 
significant decrease in the S-phase population in H28-W cells treated with SU for 24 
h. On the other hand, SU increased the subG1 population, suggesting an increase in 
the apoptotic population in both cells (Fig. 1-1-2B). It should be noted that the ratio of 
increase in the subG1 population was significantly higher in H28-T cells than in H28-
W cells. 
 
To verify that SU treatment activated the mitochondrial apoptotic pathway, followed 
by a significant increase in the subG1 population, mitochondrial membrane potential 
(⊿φM) was measured. JC-1 forms an aggregate at the mitochondria with a red 
fluorescence (600 nm) and redistributes to the cytosol as a monomer with a green 
fluorescence (535 nm) following the decrease in ⊿φM. A Change in the ratio of the 
fluorescent intensity reflects a change in ⊿φM. As expected, there was no alteration 
in H28-W cells treated with SU for 8 h, while ⊿φM in H28-T cells exposed to 10 M 
SU was significantly decreased (Fig. 1-1-3). 
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Subsequently, the activity of the RTK signaling pathway was investigated. VEGFR2 
and PDGFRβ were expressed in both H28-W and H28-T cells (Fig. 1-1-4A). The 
expression levels of these receptors were slightly lower in H28-T cells than that 
observed in H28-W cells, although there were no significant differences. The effect of 
SU on Akt and ERK, which are downstream factors of these receptors, was then 
investigated. In H28-W cells, phosphorylation of Akt was decreased after 24 h of SU 
treatment, followed by a slight decrease in the total expression after 48 h of SU 
treatment in H28-W cells, although the change was not significant (Fig. 1-1-4B). In 
contrast, in H28-T cells, the total expression of Akt was dramatically decreased in a 
time-dependent manner, which was associated with its decreased phosphorylation in 
H28-T cells. SU had no effect on both total and phosphorylated ERK expressions 
(Fig. 1-1-4C). In H28-T cells, phosphorylation of ERK significantly decreased after 24 
h of SU treatment, followed by a slight decrease in the total expression after 48 h of 
SU treatment.
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Fig. 1-1-1 SU sensitivity of Cx43-transfected cells. Cells were treated with the indicated 
concentrations of SU or DMSO (SU 0 μM) for 24 h, and cell viability was assessed by MTT 
assay. Each bar represents the mean cell viability normalized to control in each cell group, 
and vertical lines indicate S.D. of 3 independent experiments. **P < 0.01, ***P < 0.001: 
Significant difference between H28-W and H28-T cells at every SU concentration by using 
the Student’s t-test or the Aspin-Welch’s t-test. 
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Fig. 1-1-2 Estimation of cell cycle distribution and apoptosis. Cells were treated with 10 μM 
SU or DMSO (SU 0 M) for the indicated period, and each of 20,000 cells was analyzed by 
flow cytometry. (A) Alteration in cell cycle distribution in H28-W and H28-T cells in the 
presence of SU. Each bar represents the mean percentage of cells in each population, and 
vertical lines indicate S.D. of 3 independent experiments. *P < 0.05: Significant difference 
from control in each cell group, 
+
P < 0.05, 
++
P < 0.01, 
+++
P < 0.001: Significant difference 
between H28-W and H28-T cells in each control by using the Tukey-Kramer test. (B) Effect 
of SU on the induction of apoptosis detected as the pre-G
0
-G
1
 (subG
1
 population) in cell 
cycle distribution. Each bar represents the mean percentage of cells in subG
1
 population, 
and vertical lines indicate S.D. of 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 
0.001: Significant difference from control in each cell group, and 
##
P < 0.01, 
###
P < 0.001 
between H28-W and H28-T cells treated with 10 μM SU by using the Tukey-Kramer test. 
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Fig. 1-1-3 Effect of SU on mitochondrial membrane potential. Cells were treated with the 
indicated concentrations of SU or DMSO (SU 0 M) for 8 h followed by incubation with 1 
M JC-1. Each bar represents the ratio of fluorescent intensity of JC-1 aggregates at the 
mitochondria (600 nm) to JC-1 monomers in the cytosol (535 nm) normalized to control 
in each cell group, and vertical lines indicate S.D. of 8 wells. ***P < 0.001: Significant 
difference from control in each cell group by using the Tukey-Kramer test.  
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Fig. 1-1-4 Effect of SU on RTK signaling detected by western blotting. (A) Total expressions 
of VEGFR2 and PDGFRβ in H28-W and H28-T cells cultured for 48 h. Each bar represents 
the intensity of the protein bands normalized to the internal standard β-actin, and vertical lines 
indicate S.D. of 3 independent experiments. (B) Total Akt (Akt) and phosphorylated Akt (p-
Akt), and (C) total ERK (ERK) and phosphorylated ERK (p-ERK) expressions after treatment 
with 10 μM SU or DMSO (Cont) for each indicated period. Each bar represents the intensity 
of the protein bands normalized to the internal standard β-actin and is presented as a ratio 
relative to 24 h control. ERK and p-ERK includes 2 bands derived from ERK1 (✤) and ERK2 
(✤✤), and their intensities were collectively quantified. Vertical lines indicate S.D. of 3 
independent experiments. *P < 0.05, ***P < 0.001: Significant difference of control at each 
time point in each cell group by using the Tukey-Kramer test. 
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1-2 Involvement of GJ function in enhancement of SU-induced cytotoxicity 
 
In chapter 1-2, it was examined whether GJ function contributes to the enhancement 
of SU-induced cytotoxicity by using a GJ inhibitor, 18β-glycyrrhetinic acid. 
 
1-2-1 Materials and Methods 
 
Reagents  
All cultures and reagents were purchased from Sigma unless otherwise indicated.  
・6-Carboxyfluorescein (6-CF): 10 mg/mL stock solution in distilled water was used. 
・Dextran tetramethylrhodamine (DTMR; Invitrogen): 50 mg/mL stock solution in 
distilled water was used. 
・Dulbecco’s phosphate buffered saline with calcium chloride and magnesium 
chloride 
・18β-Glycyrrhetinic acid (GA): 40 mM stock solution in DMSO was used. 
・4% Paraformaldehyde phosphate buffer solution (Wako Pure chemicals) 
Refer to Chapter 1-1-1 for the used other reagents. 
 
Cell culture 
Refer to Chapter 1-1-1. 
 
Scrape loading and dye transfer assay 
A total of 5.0 × 105 H28-W cells and 1.0 × 106 H28-T cells were seeded in 35 mm 
dishes. After 24 h incubation, the cells were rinsed twice with PBS. PBS containing 
0.05% 6-CF (a GJ-permeable fluorescent dye) and 0.05% DTMR (a GJ-impermeable 
fluorescent dye) was then added to the cells before scrape loading at room 
temperature. The dye solution was left on the cells for 3 min, after which it was 
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discarded, and the cells were rinsed 3 times with PBS with calcium and magnesium. 
After that, the cells were fixed with 4% paraformaldehyde phosphate buffer solution, 
after which it was discarded, and PBS was added. Finally, the cells were observed 
under an Olympus FV500 confocal microscope (Olympus, Tokyo). GJ activity was 
assessed using 6-CF dye transfer, and the scraped edge was stained with DTMR.  
 
GJIC inhibition 
Firstly, to determine the effect of GA on GJ activity, the cells were treated with 40 μM 
GA or DMSO (control) for 24 h. Subsequently, GJ activity was assessed by using the 
scrape loading and dye transfer assay. Furthermore, to determine the effect of GJIC 
inhibition on SU cytotoxicity, the cells were treated with 40 μM GA and 0.38-10 μM 
SU for 24 h followed by the assessment of cell viability by using the MTT assay. 
Refer to Chapter 1-1-1 for the method of MTT assay. 
 
Statistical analysis 
Refer to Chapter 1-1-1. 
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1-2-2 Results 
 
At first, it was verified that a GJ-permeable 6-CF spread from the scraped edge 
stained with DTMR, suggesting the functional GJ in H28-T cells (Fig. 1-2A). 
Incubation with 40 μM GA for 24 h resulted in the inhibition of GJ function. On the 
other hand, 6-CF and DTMR were almost completely overlapped, which represents 
no GJ function in H28-W cells, and it was unchanged by GA treatment. When GA 
was combined with SU, H28-W cell viability was not altered as compared to SU alone 
(Fig. 1-2B). GA had little influence on the H28-T cell viability in conjunction with low 
doses (less than 3.3 μM) of SU, however, the combined treatment with GA and 6 or 
10 μM SU caused a significant decrease in the cell viability as compared to SU 
alone.
27 
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Fig. 1-2 Effect of GJ blockage on SU-induced cytotoxicity. (A) Effect of 18β-glycyrrhetinic 
acid (GA) on GJ function. Cells were treated with 40 μM GA or DMSO (Cont) for 24 h, and 
scrape loading and dye transfer assay. 6-CF dye transfer (green) was used to assess GJ 
function, scraped edge was stained with DTMR (red), and locations where 6-CF and DTMR 
overlapped are shown in yellow (Merge). (B) Effect of GA on SU-induced cytotoxicity. Cells 
were treated with the indicated concentrations of SU or DMSO (SU 0 μM) and 40 μM GA 
(with GA) or DMSO (without GA) simultaneously for 24 h, and cell viability was assessed by 
MTT assay. Each bar represents the mean cell viability normalized to control in each cell 
group, and vertical lines indicate S.D. of 3 independent experiments. *P < 0.05, **P < 0.01: 
Significant difference between GA-treated cells (with GA) and untreated cells (without GA) 
at every SU concentration in each cell group by using the Student’s t-test. 
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1-3 Involvement of Bax in enhancement of SU-induced cytotoxicity by Cx43 
 
In chapter 1-1, we showed that SU caused a decrease in mitochondrial membrane 
potential and increased the subG1 population in Cx43-transfected cells, suggesting 
that Cx43 expression might promote the apoptosis caused by mitochondrial 
dysfunction. Considering these results, the involvement of Bax was focused on; Bax 
is a member of the Bcl-2 family, which regulates the mitochondrial apoptotic pathway 
and is reported to directly interact with Cx43. In this chapter 1-3, it was examined 
whether Bax interacts with Cx43 and contributes to the enhancement of SU-induced 
cytotoxicity in MM cells. 
 
1-3-1 Materials and Methods 
 
Reagents  
・Fluoromount™ (Diagnostic Biosystems, Pleasanton, CA, USA) 
・Lipofectamine® 3000 Reagent (Invitrogen) 
・Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen) 
・MitoTracker® Red CM-H2XRos (MitoTracker Red; Invitrogen): 1 mM stock solution 
in DMSO was used. 
・Saponin Practical Grade (Saponin; MP Biomedicals) 
Refer to Chapter 1-1-1 for the used other reagents. 
 
Cell culture 
Refer to Chapter 1-1-1. 
 
Immunoprecipitation and western blot analysis 
A total of 1.5 × 105 H28-W cells and 3.0 × 105 H28-T cells were seeded in 60 mm 
dishes. After 6 h incubation, the cells were cultured in 0.1% FBS medium for 24 h 
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followed by treatment with 10 μM SU or DMSO (control) for each indicated period. 
Cells were collected and protein concentrations were determined as mentioned in 
Chapter 1-1. For immunoprecipitation, total cell lysates (100 μg) pre-cleared with 
protein sepharose G (GE Healthcare, Buckinghamshire, UK) for 1 h at 4°C, were 
immunoprecipitated with 3.2 μg anti-Cx43 antibody (Sigma, C6219), 1 g anti-Bax 
(N-20) antibody (Santa Cruz Biotechnology, sc-493) or anti-rabbit antibody (negative 
control) for 1 h at 4°C followed by incubation with protein sepharose G for 1 h at 4°C. 
Immunoprecipitates were washed 5 times with lysis buffer followed by resuspension 
in sample buffer and boiling for 5 min at 100°C. Then, immunoprecipitates were 
purified by centrifugation at 2300 g. Refer to Chapter 1-1-1 for the method of the 
following western blotting. The dilution/incubation conditions for the used primary 
antibodies were as follows: Cx43 (1:10000/1 h at room temperature), Bax (1:10000/1 
h at room temperature for total cell lysates, 1:2000/overnight at 4°C for 
immunoprecipitates). Both antibodies were diluted in TBS-T containing 1% skim milk.  
 
Immunofluorescence staining 
A total of 3.2 × 105 cells were seeded in a 6-well plate. After 24 h incubation, the cells 
were treated with 10 μM SU or DMSO (control) for 8 h followed by incubation with 
MitoTracker Red for 20 min at 37°C. Then, cells were fixed in 4% paraformaldehyde 
phosphate buffer solution for 20 min at 37°C. After blocking with PBS containing 
0.1% saponin and 3% BSA for 30 min at room temperature. The cells were then 
incubated with primary antibodies for 1 h at room temperature followed by incubation 
with secondary Alexa Fluor 405- or Alexa Fluor 647-conjugated antibodies diluted in 
PBS containing 0.1% saponin for 1 h at room temperature. Finally, the cells were 
observed under a Zeiss LSM 780 confocal microscope (Carl Zeiss MicroImaging 
GmbH, Jena, Germany). The dilution conditions for the used primary antibodies were 
as follows: Cx43 (1:100); Bax (6A7) (Santa Cruz Biotechnology, sc-23959) (1:50). 
Both antibodies were diluted in PBS containing 0.1% saponin and 3% BSA. Obtained 
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images were analyzed by using ImageJ2 software (National Institute of Health, 
Bethesda, MD, USA). 
 
Short-interfering RNA (siRNA) transfection 
For the Cx43 knockdown experiment, a total of 3.2 × 105 cells were seeded in a 6-
well plate. After 24 h incubation, cells were cultured in FBS-free medium shortly 
before siRNA transfection using Lipofectamine™ RNAiMAX Transfection Reagent, 
according to the manufacturer’s protocol. The following siRNAs were used: a Cx43-
specific siRNA (Hs_GJA1_5); a negative control siRNA (AllStars Negative Control 
siRNA). Cells were transfected with a final amount of 50 pmol siRNA for 24 h, and 
then used for the immunofluorescence staining as mentioned above. 
For the Bax knockdown experiment, a total of 2.2 × 105 H28-T cells were seeded in a 
6-well plate. After 6 h incubation, the cells were cultured in medium containing 0.1% 
FBS shortly before siRNA transfection using Lipofectamine® 3000 Reagent, 
according to the manufacturer’s protocol. The following siRNAs were used: a Bax-
specific siRNA (Hs_BAX_10); a negative control siRNA. Cells were transfected with a 
final concentration of 10 nM siRNA for 24 h, and then used for the western blotting 
and the flow cytometry. Refer to Chapter 1-1-1 for the method of each experiment. 
All the used siRNAs were obtained from Qiagen (Valencia, CA, USA). 
 
Statistical analysis 
Refer to Chapter 1-1-1. 
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1-3-2 Results 
 
Bax (23 kilodaltons) and Cx43 (~43 kilodaltons) were immunoprecipitated from the 
total cell lysates of SU-treated and untreated H28-T cells by using an anti-Cx43 
antibody or an anti-Bax (N-20) antibody, respectively (Fig. 1-3-1). The total Bax 
expression level was slightly higher in H28-T cells compared with H28-W cells, 
although the difference was not statistically significant (Fig. 1-3-2A). SU had almost 
no effect on the total Bax expression level in both cells (Fig. 1-3-2B). However, a 
putative Bax dimer band over 35 kilodaltons was detected only in H28-T cells, and 
SU treatment increased the density of this band. Bax mainly exists in the cytosol as 
an inactive monomer in intact cells, and apoptotic stimuli cause Bax to change 
conformation with its N-terminus exposure (active Bax) and then to translocate to the 
mitochondria and to form dimers/oligomers; finally, the Bax oligomers result in 
mitochondrial dysfunction.  
 
To investigate whether the SU treatment of MM cells promotes the process of Bax 
activation, immunofluorescence staining was performed by using an anti-Bax (6A7) 
antibody that specifically recognizes N-terminus of active Bax. As shown in Fig. 1-3-
3, no expression of active Bax was detected in both SU-treated and untreated H28-W 
cells, which do not express Cx43 protein. In contrast, in H28-T cells, SU treatment 
caused cell shrinkage, increased active Bax expression and its accumulation at the 
mitochondria. More importantly, the observation of dozens of H28-T cells showed that 
both total expression level and the ratio of mitochondrial localization of active Bax 
were significantly increased by SU treatment, and these were suppressed by the 
knockdown of Cx43 (Fig. 1-3-4).  
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Finally, the knockdown of Bax was performed to assure that Bax activation 
contributes to induction of apoptosis. As expected, the depletion of Bax expression 
significantly reduced the ratio of subG1 population in the presence of SU, though cell 
cycle distribution was not affected (Fig. 1-3-5). 
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Fig. 1-3-1 Interaction between Cx43 and Bax. Cells were treated with 10 μM SU or DMSO 
(Cont) for 24 h, and immunoprecipitation (IP) from H28-T cell extract was performed using 
an anti-Cx43 antibody, an anti-Bax antibody or an anti-rabbit antibody (negative control, 
NC) followed by western blotting (WB). (A) Bax was detected, and an arrow represents its 
band. (B) Cx43 was detected, and each arrow represents a non-phosphorylated (✤) and a 
phosphorylated (✤✤) form, respectively. Each photo is representative of 3 independent 
experiments. 
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Fig. 1-3-2 Difference of Bax behaviors in H28-W and H28-T cells detected by western 
blotting. (A) Total Bax expression in naïve H28-W and H28-T cells. Each bar represents the 
intensity of the protein bands normalized to the internal standard β-actin, and vertical lines 
indicate S.D. of 3 independent experiments. (B) Effect of SU on Bax expression in H28-W 
and H28-T cells. Cells were treated with 10 μM SU or DMSO (Cont) for 24 h. β-Actin is 
shown as the internal standard. Each arrow represents a monomer (✤) and a dimer (✤✤) 
form, respectively. Each photo is representative of 3 independent experiments. 
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Fig. 1-3-3 Effect of SU on Bax activation in H28-W and H28-T cells detected by 
immunofluorescence staining. Cells were treated with 10 μM SU or DMSO (Cont) for 8 h 
followed by incubation with MitoTracker Red to be stained for mitochondria (red). After 
fixation, cells were treated with anti-Cx43 antibody (blue) and anti-Bax (6A7) antibody 
(green). Anti-Bax (6A7) antibody recognizes active Bax. Yellow areas represent where the 
mitochondria and active Bax are overlapped. 
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Fig. 1-3-4 Effect of Cx43 knockdown on SU-induced Bax activation in H28-T cells. Cells 
were transfected with a final amount of 50 pmol Cx43-specific siRNA (siCx43) or negative 
control (NC) siRNA for 24 h followed by treatment with 10 μM SU or DMSO (Cont) for 8 h 
and incubation with MitoTracker Red to be stained for mitochondria (red). After fixation, 
cells were treated with anti-Cx43 antibody (blue) and anti-Bax (6A7) antibody (green). Anti-
Bax (6A7) antibody recognizes active Bax. Yellow areas represent where the mitochondria 
and active Bax are overlapped. (A) Each photo is representative of the observed cells in 
each group. (B) Box plots show the total expression of Cx43 (n = 17-20). (C) Box plots show 
the total expression of active Bax (left) and the ratio of active Bax localized at the  
mitochondria to total active Bax expression (right) (n = 27-30). **P < 0.01, ***P < 0.001: 
Significant difference from control in each siRNA treatment group, and 
##
P < 0.01, 
###
P < 
0.001: Significant difference between siBax and NC treated with 10 μM SU by using the 
Tukey-Kramer test. 
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Fig. 1-3-5 Effect of Bax knockdown on SU-induced alteration in cell cycle distribution and 
induction of apoptosis in H28-T cells. (A) Effect of siRNA treatment on Bax protein 
expression. Cells were transfected with a final concentration of 10 nM Bax-specific siRNA 
(siBax) or negative control (NC) siRNA for 24 h, and protein expression was detected by 
western blotting. β-Actin is shown as the internal standard. (B, C) Effect of siRNA treatment 
on cell cycle distribution and induction of apoptosis detected as the pre-G
0
-G
1
 (subG
1
 
population) in cell cycle distribution in the presence of SU. Cells were transfected with a 
final concentration of 10 nM Bax-specific siRNA or NC siRNA for 24 h followed by treatment 
with 10 μM SU or DMSO (SU 0 M) for 48 h. Each of 20,000 cells was analyzed by flow 
cytometry. Each bar represents the mean percentage of cells in each population, and 
vertical lines indicate S.D. of 3 independent experiments. ***P < 0.001: Significant difference 
from control in each siRNA treatment group, and 
###
P < 0.001: Significant difference between 
siBax and NC treated with 10 μM SU by using the Tukey-Kramer test. 
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1-4 Discussion  
 
In this chapter, the potential of Cx43, the well-studied Cx subtype, to enhance the 
activity of SU in MM cells was investigated. We used a human MM cell line H28, 
which has no detectable Cx43 protein expression and functional GJ. The sensitivity 
to SU was compared between H28-T cells (Cx43-transfected cells) and H28-W cells 
(parental cells). 
 
First, we assessed the difference in SU-induced cytotoxicity between H28-W and 
H28-T cells. The cell viability test showed that the cytotoxic effect of SU was greater 
in H28-T cells than in H28-W cells (Fig. 1-1-1). In particular, the difference in cell 
viability was the greatest in the presence of 10 μM SU. This concentration is high 
compared to clinical plasma concentration after oral administration (0.125-0.25 M), 
although it falls within the commonly used range in vitro study (36). It is reported that 
tumor tissues from human and mouse administered SU contained approximately 10 
M SU (37). SU is a multi-targeted tyrosine kinase inhibitor, which is hydrophobic 
(logP = 5.2) and a weak base (pKa = 8.95). These characteristics allow SU to easily 
pass through the plasma membrane and to be trapped in the acidic lysosome, 
leading to its accumulation in cells. Thus, we considered that the concentration was 
reasonable, and 10 M SU was mainly used in the following experiments.   
 
In the evaluation of the effect of SU on the cell cycle, we observed that SU had 
almost no influence except for a significant decrease in S-phase population and the 
corresponding increase in G1-phase population after 24 h of SU treatment of H28-W 
cells (Fig. 1-1-2A). Interestingly, when the cell cycle population was compared 
between untreated H28-W and H28-T cells, a significantly higher S-phase population 
was observed in H28-T cells compared with the H28-W cells at every time point. This 
tendency was also observed in the previous work (14). SU treatment caused a 
42 
 
significant increase in the size of the subG1 population in both cells, and that 
population of H28-T cells treated with 10 μM SU was significantly larger than in that 
of SU-treated H28-W cells (Fig. 1-1-2B). Treatment with low concentrations (less 
than 3.3 μM) of SU had no effect on the induction of apoptosis and cell cycle 
distribution in both cells (data not shown). Based on these results, we infer that the 
greatest difference in cell viability between H28-W and H28-T cells in the presence of 
10 μM SU is derived from the efficient induction of cell death in H28-T cells. 
Furthermore, 10 μM SU resulted in a significant decrease in the mitochondrial 
membrane potential in H28-T cells, while no alteration was detected in H28-W cells 
(Fig. 1-1-3). It is suggesting that SU treatment causes mitochondrial dysfunction in 
H28-T cells, but not in H28-W cells.  
 
Next, we assessed the effect of SU on RTK signaling. In H28-T cells, total Akt 
expression was almost undetectable, and phosphorylation of ERK was significantly 
suppressed by SU treatment (Fig. 1-1-4B, C). These results indicate that increased 
Cx43 expression enables SU to effectively suppress RTK signaling. The decrease in 
Akt expression most likely occurred due to the induction of apoptosis, since it is 
known that Akt is cleaved and inactivated by caspases in process of apoptotic cell 
death (38). Inhibition of ERK phosphorylation is thought to have contributed to the 
growth inhibition, because ERK normally promotes cell cycle progression from G1- to 
S-phase through upregulation of cyclin D, which contributes to cell proliferation (39). 
Previously, we confirmed that total and phosphorylated ERK expressions were higher 
in naïve H28-T cells than in H28-W cells (data not shown). Taken together the report 
that ERK signaling is activated by GJIC (40), we infer that the GJIC-activated ERK 
signaling results in a higher S-phase population in H28-T cells than in H28-W cells. In 
contrast, it has been pointed out that sustained activation of ERK promotes apoptosis 
(41). Liu et al. showed that ERK increased the expression of proapoptotic factors 
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such as Bax and p53-upregulated modulator of apoptosis (PUMA), through p53 
phosphorylation (42). In fact, total Bax expression was higher in H28-T cells than in 
H28-W cells (Fig. 1-3-2A), which is thought to be related to the rapid apoptotic 
process in H28-T cells exposed to SU. 
 
We then investigated the mechanism by which Cx43 enhances SU-induced 
cytotoxicity. As mentioned above, Cx appears to have an influence on the drug 
sensitivity of cancer cells through both GJ-dependent and GJ-independent 
mechanisms; the GJ-dependent mechanism is known as a “bystander effect”. This is 
the effect where an anti-cancer agent itself or a death signal is transmitted 
throughout a tumor via GJ channels. The combination of herpes simplex virus gene 
therapy and ganciclovir administration working through this effect is well documented 
with a positive outcome in malignant glioma patients in a phase I clinical trial (43). 
Moreover, it has been shown that the restoration of GJ function improves the anti-
proliferative effects of various types of agents including gemcitabine (44), cisplatin 
(45), and sorafenib (46). The fact that GJ can pass molecules up to 1200 daltons 
(47), and SU is a small molecule of approximately 400 daltons, suggests that SU 
may be directly transferred between cells via GJs. To investigate the involvement of 
GJ function in enhancing the cytotoxic effect of SU, a pharmacological GJ inhibitor, 
18β-glycyrrhetinic acid (GA) was used in the present study. It was expected that GA 
treatment would attenuate the cytotoxicity of SU in H28-T cells. However, GJ 
inhibition did not modulate the viability of H28-T cells treated with low concentrations 
of SU (Fig. 1-2B). The combined treatment with GA and 6 or 10 M SU rather 
decreased H28-T cell viability in comparison to SU alone. The result obtained may 
come from the ambiguous characteristic of GJ; GJ normally contributes to 
maintaining intracellular homeostasis, and it is believed that cell damage causes 
transfer of survival signals or dilution of death signals through GJ (48). In other 
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words, GJ provides both cell survival and cell death signals depending on the 
situation (49). In the present study, GJ seems to play a protective role against the cell 
damage that is caused by high concentrations of SU. However, there remains the 
possibility that GA caused off-target effect, and it might relate to the reported 
mechanism by which GA inhibits GJ function by modulating the phosphorylation 
status of Cx proteins, leading to GJ disassembly (50). It relates to the activation of 
protein kinase C (PKC), which has a potential to affect the function of various 
proteins. Thus, while the contribution of GJ cannot be completely excluded by this 
experiment, additional GJ inhibitors should be investigated in combination with SU to 
conclude the involvement of GJ. 
 
In investigating the GJ-independent mechanism, we hypothesized that Cx43 
modulates the expressions or functions of some pro or antiapoptotic proteins 
including Src (6) and Bax (9) in a GJ-independent manner. In the present work, we 
focused on the proapoptotic factor Bax, since the induction of apoptosis was notable. 
In fact, Bax was confirmed to directly interact with Cx43 (Fig. 1-3-1). A Cx43-specific 
antibody reacted to several Cx43 proteins with different molecular size from H28-T 
cell lysate immunoprecipitated using a Bax-specific antibody. The upper band 
observed may be phosphorylated forms of Cx43, although further investigations are 
needed. As shown in Fig. 1-3-2B, a Bax dimer was detected only in H28-T cells, and 
SU treatment increased the expression of this form of dimeric Bax. Bax forms 
dimers/oligomers at the mitochondria and results in the decrease in mitochondrial 
membrane potential (51), the appearance of dimer forms indicates that Bax was 
activated and promoted apoptosis in H28-T cells. The results exhibited in Fig. 1-3-2 
are interesting findings; the bigger size Bax among the 2 detected bands was more 
clearly expressed in H28-T cells than in H28-W cells, and a Bax dimer was detected 
even in intact H28-T cells. Bax has at least 9 splice variants, and the Bax-specific 
45 
 
antibody used can detect alpha, beta, and delta isoforms. Considering that Bax alpha 
is the common 21 kilodalton isoform, and only beta and omega transcripts would 
yield products with higher molecular size than the alpha isoform, the bigger size 
molecule may be a 24 kilodalton Bax beta isoform (52). It is reported that the Bax 
beta is constantly degraded by the proteasomal system, although it has a greater 
potential to cause apoptosis than the alpha isoform; it naturally translocates from the 
cytosol to the mitochondria and forms oligomers there without any stimulus. It is 
corresponding to the appearance of dimer in naïve H28-T cells shown in Fig. 1-3-2B. 
Moreover, it seems that Cx43 interacts with the 24 kilodalton Bax isoform (Fig. 1-3-
1A). These results suggest that Cx43 interacts with Bax beta and stabilizes its 
expression. To verify that Bax changes its conformation and translocates to the 
mitochondria, an antibody detecting the N-terminus region of Bax, which is exposed 
only in the active form, was used in immunofluorescence staining. As shown in Fig. 
1-3-3, both total expression and ratio of localization at the mitochondria clearly 
increased in H28-T cells after SU treatment, while there was no detectable active 
Bax in H28-W cells. Moreover, the increased total expression and the subsequent 
translocation to the mitochondria induced by SU in H28-T cells were significantly 
decreased by the knockdown of Cx43 (Fig. 1-3-4A, C). These results suggest that 
the presence of Cx43 was crucial for the process of Bax activation.  
 
Finally, the results of the knockdown of Bax expression reduced the ratio of subG1 
population in H28-T cells treated with SU, which indicates that Bax is involved in SU-
induced apoptosis (Fig. 1-3-5). It is reported that H28 cells express another 
proapoptotic Bcl-2 family protein Bak (53), and it may also contribute to induction of 
apoptosis in both H28-W and H28-T cells. However, the Bax knockdown in H28-T 
cells showed approximately 50% reduction in apoptotic ratio, which suggests that 
Bax is the major proapoptotic protein in these cells.
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1-5 Summary 
 
In Cx43-transfected H28 cells, the following results were obtained;  
 
 Growth inhibitory effect of SU was enhanced 
 
 Inhibitory effect of SU on RTK signaling was enhanced 
 
 Apoptosis was notably induced by SU 
 
 GJ function had little effect on enhancement of SU-induced cytotoxicity 
 
 Mitochondrial dysfunction was observed after SU treatment 
 
 Process of Bax activation was detected 
(Conformational change, translocation to mitochondria, and oligomerization) 
 
 The presence of Cx43 was crucial for process of Bax activation 
 
 Bax was involved in induction of apoptosis 
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Chapter 2 JNK intermediates interaction between Cx43 and Bax 
 
Introduction 
 
In the previous chapter, we elucidated that the interaction between Cx43 and Bax 
was a key to enhance SU-induced cytotoxicity in MM cells. To investigate the 
mechanism by which Cx43 affects Bax activity, localization of Cx43 is important, as it 
forms an intercellular channel and is mainly localized at the plasma membrane. On 
the other hand, several studies have suggested that it is also localized at the 
mitochondrial membrane (54, 55). These reports suggest that approximately 4% of 
total Cx43 was localized at the mitochondria obtained from human umbilical vein 
endothelial cells (HUVEC) and a whole rat ventricles, respectively. Our preliminary 
data showed that Cx43 proteins were localized at the mitochondria in H28-T cells, 
while most of them seemed to be near the plasma membrane. Taken the result from 
Fig. 1-3-1 together, two possible pathways can be assumed as mechanisms by 
which Bax was activated by Cx43; (1) Cx43 at the plasma membrane directly actives 
Bax, or it serves as a docking platform for Bax and another protein for the promotion 
of Bax translocation to the mitochondria. (2) Cx43 at the mitochondrial membrane 
directly or indirectly stabilizes localization of Bax at the mitochondria. This study 
focused on the former hypothesis, since active Bax was frequently detected not only 
at the mitochondria, but also near the plasma membrane.  
 
In this chapter, a potential involvement of c-jun N-terminal kinase (JNK), a member of 
the mitogen-activated protein kinase (MAPK) family, in the interplay of Cx43 and Bax 
was examined; it is known that this serine/threonine kinase phosphorylates 
threonine167 in Bax and then promotes Bax translocation to the mitochondria (56). In 
addition, because another MAPK family member ERK directly interacts with Cx43 
(57), it is plausible that JNK may also interact with Cx43.
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2-1 Materials and Methods 
 
Reagents  
・SP600125 (SP; Wako Pure Chemicals): 50 mM stock solution in DMSO was used. 
Refer to Chapter 1-1-1 and 1-3-1 for the used other reagents. 
 
Cell culture 
Refer to Chapter 1-1-1. 
 
Western blot analysis 
Refer to Chapter 1-1-1 for the method. The dilution/incubation conditions for the used 
primary antibodies were as follows: JNK2 (56G8) (Cell Signaling Technologies, 
#9258) (1:5000 diluted in TBS-T containing 1% skim milk /1 h at room temperature); 
Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) (Cell Signaling Technologies, #4668) 
(1:1000 diluted in TBS-T containing 5% BSA /overnight at 4°C).  
 
Immunofluorescence staining 
For the inhibition of JNK activity, 24 h after seeding, cells were treated with 5 or 10 
μM SP for 30 min before exposure to 10 μM SU or DMSO (control) for 8 h. Refer to 
Chapter 1-3-1 for the following procedure. The dilution condition for the used primary 
antibody was as follows: JNK1+JNK2 (phospho T183+Y185) (Abcam, Cambridge, 
UK, ab4821) (1:50). 
 
siRNA transfection 
Refer to Chapter 1-3-1 for the method of the Cx43 knockdown experiment. 
 
Statistical analysis 
Refer to Chapter 1-1-1. 
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2-2 Results 
 
Changes in both the phosphorylation status and the total expression of JNK were 
investigated by western blotting. There were 2 different bands on the membrane 
detecting both phosphorylated and total JNK. In H28-W cells, no alteration was 
observed due to SU treatment in both the phosphorylation status and the total 
expression (Fig. 2-1). In contrast, in H28-T cells, SU treatment induced obvious 
changes: increase in the total expression of JNK with smaller molecular weight and 
the phosphorylation of both JNK proteins, clearly identifying JNK activation only in 
Cx43-transfected H28-T cells. 
 
Then, the effect of Cx43 knockdown on JNK activation in H28-T cells was observed. 
Fig. 2-2A shows the representative images in negative control siRNA-treated cells 
exposed to SU for 1 h. Weak signals derived from phosphorylated JNK were 
detected in the nucleus, and stronger punctate signals were scattered in the cytosol. 
Spotted signals derived from active Bax was also detected. The merged image 
shows that phosphorylated JNK and active Bax were partly colocalized. More 
importantly, phosphorylation of JNK was decreased, and active Bax was almost 
undetectable in Cx43-specific siRNA-treated cells (Fig. 2-2B). 
 
Finally, the relationship between JNK activation and Bax activation was investigated 
by using a JNK inhibitor, SP600125 (SP). After 8 h of SU treatment, phosphorylated 
JNK was strongly expressed in the nucleus. Pretreatment with SP efficiently 
suppressed SU-induced JNK activation (Fig. 2-3A, B). Additionally, SP treatment also 
suppressed Bax activation in a dose-dependent manner, accompanied by a slight 
decrease in localization ratio at the mitochondria (Fig. 2-3C). 
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Fig. 2-1 Effect of SU on JNK activity in H28-W and H28-T cells detected by western blotting. 
Total JNK (JNK) and phosphorylated JNK (p-JNK) expressions after treatment with 10 μM 
SU or DMSO (Cont) for 8 h are shown. β-Actin is shown as the internal standard. Each 
photo is representative of 2 or 3 independent experiments. 
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Fig. 2-2 Effect of Cx43 knockdown on SU-induced JNK and Bax activation in H28-T cells. 
Cells were transfected with a final amount of 50 pmol Cx43-specific siRNA (siCx43) or 
negative control (NC) siRNA for 24 h followed by treatment with 10 μM SU for 1 h. After 
fixation, cells were treated with anti-phosphorylated JNK (p-JNK) antibody (magenta) and 
anti-Bax (6A7) antibody (green). Anti-Bax (6A7) antibody recognizes active Bax. (A) NC 
siRNA-treated group. Areas surrounded by quadrangles in upper images were magnified 
shown as lower ones. Arrows represent locations where p-JNK and active Bax are 
overlapped (white). (B) Cx43-specific siRNA-treated group. Each photo is representative 
of 2 independent experiments. 
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Fig. 2-3 Effect of JNK inhibition on SU-induced Bax activation in H28-T cells. Cells were 
treated with 5 or 10 M SP600125 (SP) or DMSO (Cont) followed by treatment with 10 
μM SU or DMSO (Cont) for 8 h and incubation with MitoTracker Red to be stained for 
mitochondria (red). After fixation, cells were treated with anti-phosphorylated JNK (p-JNK) 
antibody (magenta) and anti-Bax (6A7) antibody (green). Anti-Bax (6A7) antibody 
recognizes active Bax. Yellow areas represent where the mitochondria and active Bax are 
overlapped. (A) Each photo is representative of the observed cells in each group. (B) Box 
plots show the total expression of p-JNK (n = 3-9). (C) Box plots show the total expression 
of active Bax (left) and the ratio of active Bax localized at the mitochondria to total active 
Bax expression (right) (n = 3-9). **P < 0.01: Significant difference between Cont and SU, 
and 
#
P < 0.05, 
##
P < 0.01, 
###
P < 0.001: Significant difference from SU by using the Tukey-
Kramer test. 
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2-3 Discussion  
 
In general, treatment with anti-cancer agents causes oxidative stress, which is one of 
the major inducers of mitochondrial dysfunction. Drug-induced oxidative stress 
activates JNK and p38, both of which are known as stress-activated protein kinases 
(SAPKs) in the MAPK family (58, 59). This family includes ERK other than JNK and 
p38, and these serine/threonine kinases have the common structure including an A-
loop (activation site phosphorylated by upstream kinases), a D-domain (allosteric 
site) and a kinase domain (60). Each kinase is activated by upstream MAPK kinases, 
which phosphorylates substrates like transcription factors, c-Jun and c-Fos (61). As 
mentioned in the introduction of this chapter, Bax is one of the substrates for JNK 
(56). Thus, we hypothesized that JNK is involved in SU-induced Bax activation. 
 
Investigating the effect of SU on JNK activity, we verified that JNK phosphorylation 
was notably increased in H28-T cells, while no alteration was observed in H28-W 
cells (Fig. 2-1). Detection of JNK protein by western blotting showed 2 different 
bands in both phosphorylated and total JNK. JNKs are encoded by 3 genes, and 
each product produces low and high molecular weight splice variants (46-49 and 54-
57 kilodaltons, respectively) (62). JNK3 is expressed specifically in the brain (63), 
and a JNK2-specific antibody was used to detect total expression, therefore, it is 
rational to think that products derived from JNK2 were detected as total JNK in the 
present study. Almost the same total expression level of high molecular weight 
product was detected in both cells, while that of low molecular weight product was 
demonstrably higher in naïve H28-T cells than in H28-W cells, and SU treatment 
increased this expression in H28-T cells. There are 4 isoforms derived from JNK2, 2 
of which give the high molecular weight products and the others give low molecular 
weight ones. It is reported that there was a difference in the binding potential for c-
Jun among the isoforms, while there was no relationship between the binding 
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potential and molecular size (64). Moreover, all products from both JNK1 and JNK2 
have activation motif (threonine-proline-tyrosine), whose dual phosphorylation 
products were detected as phosphorylated JNK by the antibody used in the present 
study. Thus, there is the possibility that the detected phosphorylated JNKs contain 
products from both genes. Such diversity in JNK expression makes it difficult to 
identify which isoform reacted to SU-induced stress without further investigations.  
 
There still remains a question; why JNK was not activated in H28-W cells? A 
potential reason may be due to the difference in metabolism between H28-W and 
H28-T cells. It is reported that H28 depends on glycolysis to obtain adenosine 
triphosphate (ATP) (65). The glycolytic pathway branches to the pentose phosphate 
pathway, which supplies reduced nicotinamide adenine dinucleotide phosphate 
(NADPH). This may result in an abundance of NADPH and cause the resistance to 
SU-induced oxidative stress and the following JNK activation in H28-W cells, as 
NADPH is required for scavenging reactive oxygen species (ROS) (66). On the other 
hand, it is also suggested that mitochondrial Cx43 is involved in mitochondrial 
respiration, which consumes oxygen (67). From these reports, it can be thought that 
increased Cx43 expression at the mitochondria shifts cell metabolism preference 
from anaerobic glycolysis to aerobic respiration following the increased sensitivity to 
oxidative stress. Totally, the presence of Cx43 seems to promote JNK activation. 
 
In the next step, the interaction between the phosphorylated form of JNK (derived 
from both JNK1 and JNK2) and active Bax was investigated by immunofluorescence 
staining. After 1 h of SU treatment, phosphorylated JNK was localized in both the 
cytosol and nucleus, although expression level was low in the nucleus (Fig. 2-2A). It 
can be surmised that JNK was activated in the cytosol and then translocated to the 
nucleus, since active JNK was mainly localized in the nucleus after 8 h of SU 
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treatment (Fig. 2-3A). Considering that MAPKs are activated by their upstream 
kinases in the cytosol and transduce the signal to transcription factors, the observed 
dynamic change of phosphorylated JNK seems reasonable. Active Bax was also 
sparsely detected after 1 h of SU treatment. Phosphorylated JNK and active Bax was 
partly colocalized, which suggests that they directly contacted. The most important 
observation in these investigations is that JNK activation was decreased and Bax 
activation was inhibited by the Cx43 knockdown (Fig. 2-2B). These results suggest 
that Cx43 enhances activation of both JNK and Bax at an early point. Direct inhibition 
of JNK activity by a pharmacological JNK inhibitor clearly decreased active Bax 
expression (Fig. 2-3B, C), suggesting that activated JNK has an impact on Bax 
conformational change. It is not so surprising that the decrease in mitochondrial 
localization was modest; it is assumed that once activated, Bax rapidly translocates 
to the mitochondria, and therefore, JNK inhibition had a little impact on the 
localization of active Bax.  
 
Based on the results of this chapter, it is expected that Cx43 may promote activation 
of JNK and the interaction of it with Bax. In future studies, the direct interaction 
between Cx43 and JNK should be verified, and the mechanism by which Cx43 
activates JNK needs to be investigated. Oxidative stress causes oxidation of various 
kinds of proteins followed by the alteration in their function. For example, oxidation of 
PKC gamma increases its kinase activity and promotes its translocation to the 
plasma membrane and the interaction with Cx43 (68). Thus, it is reasonable to 
expect that another kinase including PKC gamma activates JNK in cooperation with 
Cx43. In addition, it should be verified that the detected “active Bax” is equivalent to 
the reported “Bax phosphorylated at threonine167”. As discussed in the previous 
chapter, it is important to clarify which Bax isoform interacts with Cx43, since Bax 
alpha and Bax beta have a different amino acid sequence in C-terminus region, and 
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Bax beta lacks threonine167. Instead, it has threonine185, which is a candidate residue 
to be phosphorylated, and there is a lack of information regarding the 
phosphorylation sites in Bax beta. As for phosphorylation, there remains the 
possibility that modulation of phosphorylation of serine184, which is another critical 
phosphorylation site in Bax alpha, is also a key for Cx43-mediated Bax activation 
(51). Thus, more investigation into the involvement of kinases other than JNK may 
clarify the mechanism of the interaction between Cx43 and Bax. 
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2-4 Summary 
 
 JNK was activated by SU treatment only in Cx43-transfected cells 
 
 The presence of Cx43 was crucial for early activation of both JNK and Bax 
after SU treatment 
 
 JNK activation promoted Bax activation 
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Conclusion 
  
In this study, the significance of the interaction between Cx43 and Bax in drug-
induced apoptosis was evaluated by using a combination of Cx43-transfected MM 
cells and SU. The findings obtained are summarized below. 
 
The effect of Cx43 on SU-induced cytotoxicity was evaluated in chapter 1. 10 M SU 
caused apoptotic cell death in MM cells, and it was enhanced by increased Cx43 
expression. The enhancement of SU cytotoxicity due to inhibition of the RTK 
signaling pathway was augmented in Cx43-transfected cells, while SU failed to 
suppress that pathway in parental cells with no detectable Cx43 protein. 
Furthermore, GJ function had little contribution to the mechanism by which Cx43 
enhanced the cytotoxicity of SU.  
Thus, the present study focused attention to Bax, a master regulator of apoptosis. 
The Cx43 knockdown experiment showed that Cx43 was important for SU-induced 
Bax conformational change and translocation to the mitochondria. Moreover, a Bax 
dimer was detected only in Cx43-transfected cells. In Bax-specific siRNA-treated 
cells, the apoptotic ratio was decreased to approximately 50% of the control post-SU 
treatment, which indicates that Bax largely contributed to the promotion of apoptosis 
in Cx43-transfected cells.  
Taken together, these results highlight the importance of the interaction between 
these proteins for induction of apoptosis. 
 
A detailed mechanism was investigated in chapter 2. Treatment with anti-cancer 
agents generally causes ROS production, which activates JNK also known as SAPK. 
Considering the report that showed that phosphorylation of Bax by JNK promotes 
Bax activation, we hypothesized that JNK may affect the interplay between Cx43 and 
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Bax. Investigating this aspect, we found that SU treatment increased both total 
expression and phosphorylation of JNK only in Cx43-transfected cells. The 
subsequent Cx43 knockdown experiment showed that Cx43 had a crucial role in 
early JNK activation caused by SU. JNK inhibition efficiently reduced expression of 
active Bax, which suggests that activated JNK contributed to Bax activation. 
 
Fig. 3 illustrates the role of Cx43 in SU-induced apoptosis. The current investigations 
have identified a novel Cx43-JNK-Bax apoptotic axis that enhances the cytotoxicity of 
SU in MM cells. 
 
 
 
 
 
 
 
 
 
Although a combination of other Cx subtypes and anti-cancer agents should be 
investigated to generalize this axis, the current finding suggests the important role of 
Cx in protein-protein interactions that are beyond its original role in GJs. Increasing 
Bax function is corresponding the latest chemotherapeutic strategy to directly target 
the Bax protein, and some direct Bax activators have been already identified and 
showed promising results both in vitro and in vivo (69).  
 
Fig. 3 Scheme of the mechanism by which Cx43 enhances SU-induced cytotoxicity. 
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An overview of our research depicted in Fig. 4 shows that both Cx43 and Cx32 can 
enhance the drug-induced cytotoxicity. While these studies have mainly focused on  
the molecular interaction of Cx protein, at the same time, the involvement of GJ also 
seems to partly contribute to the enhancement of cytotoxicity of several anti-cancer 
agents as shown in earlier studies by us as well as others (16, 17, 44, 45). Recently, 
some groups have reported that GJ allows microRNAs to be transferred between 
cancer cells or cancer cells and the neighboring normal cells, which affects 
phenotypes of cancer cells including the potential of invasion and angiogenesis (70, 
71). GJ-mediated direct transfer of small molecules may overcome problems, 
especially in vivo, since the center of a tumor is generally far from a blood vessel and 
is difficult to be directly perfused by anti-cancer agents.  
 
There are many challenges to be resolved for application of Cx to clinical cancer 
therapy: for instance, the technical challenge to selectively enhance expression or 
function of Cx in target tumors. Its pluripotency raises the concern regarding off-
target and side effects. Nevertheless, Cx is one of the attractive targets for cancer 
therapy, and further investigations into the role of Cx in protein-protein interactions as 
well as the role in GJs will promote its application in clinical therapeutic benefits. 
Fig. 4 Overview of whole our study regarding combination of Cxs and anti-cancer agents. 
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